Medea Medical

Medea Medical is on the verge of certifying its collagen-based hemostatic agent, Novacol®, under the new CE-MDR regulations. What sets Novacol® apart is not merely its hemostatic function, but its ability to eliminate two critical risks: swelling and slow resorption. Swelling poses an immediate threat to surrounding tissue, particularly in neurosurgery, while slow resorption increases the risk of postoperative infections. Novacol® offers a safe, rapidly resorbable alternative at a competitive price. The upcoming phase focuses on scaling up: building inventory, establishing an efficient supply chain, and launching new sales and distribution channels across multiple international key markets.